Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2

Cancer Research

Volumn 66, Issue 9, 2006, Pages 4872-4879

  Wu, Joyce ^a   Lee, Cathy ^a   Yokom, Daniel ^a   Jiang, Helen ^a   Cheang, Maggie C U ^b   Yorida, Erika ^b   Turbin, Dmitry ^b   Berquin, Isabelle M ^c   Mertens, Peter R ^d   Iftner, Thomas ^e   Gilks, C Blake ^b   Dunn, Sandra E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c WAKE FOREST UNIVERSITY   (United States)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; SMALL INTERFERING RNA; Y BOX BINDING PROTEIN 1;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CHROMATIN; DNA BINDING; DRUG BINDING; GENE CONTROL; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR GROWTH;

BREAST NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; PROMOTER REGIONS (GENETICS); RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; Y-BOX-BINDING PROTEIN 1;

EID: 33646394318     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3561     Document Type: Article

References (44)

1. Sakura H, Haekawa T, Imamoto F, Yasuda K, Ishii S. Two human genes isolated by a novel method encode DNA-binding proteins containing a common region of homology. Gene 1988;73:499-507.
2. Bargou RC, Jurchott K, Wagener C, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997;3:447-50.
3. Gimenez-Bonafe P, Fedoruk MN, Whitmore TG, et al. The transcription factor Yb-1 is upregulated during prostate cancer progression and increases P-glycoprotein expression. Prostate 2004;59:337-49.
4. Shibao K, Takano H, Nakayama Y, et al. Enhanced coexpression of YB-1 and DNA polymerase II genes in human colorectal carcinomas. Int J Cancer 1999;83:732-7.
5. Yahata H, Kobayashi H, Kamura T, et al. Increased nuclear localization of transcription factor Yb-1 in acquired cisplatin-resistance ovarian cancer. J Cancer Res Clin Oncol 2002;128:621-6.
6. Shibahara K, Sugio K, Osaki T, et al. Nuclear expression of Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 2001;7:3151-5.
7. Oda Y, Sakamoto A, Shinohara N, et al. Nuclear expression of Yb-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res 1998;4:2273-7.
8. Bergmann S, Royer-Pokora B, Fietze E, et al. YB-1 provides breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res 2005;10:4078-87.
9. Rubinstein DB, Stortchevoi A, Bossalis M, Ashfaq R, Guillaume T. Overexpression of DNA-binding protein B gene product in breast cancer detected by in vitro-generated combinatorial human immunoglobulin libraries. Cancer Res 2002;62:4985-91.
10. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
11. Jurchott K, Bergmann S, Stein U, et al. Yb-1 as a cell cycle regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem 2003;278:27988-96.
12. Swamynathan SK, Varma BR, Weber KT, Guntaka RV. Targeted disruption of one allele of the Y-box protein gene, Chk-YB-1b in DT40 cells results in major defects in cell cycle. Biochem Biophys Res Commun 2002;296:451-7.
13. En-Nia A, Yilmaz E, Klinge U, Lovett DH, Stefanidis I, Mertens PR. Transcription factor YB-1 mediates DNA polymerase alpha gene expression. J Biol Chem 2004;280:7702-11.
14. 102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 2005;24:4281-92.
15. Kloks CPAM, Spronk CAEM, Lasonder E, et al. The solution structure and DNA-binding properties of the cold-shock domain of the human Y-box protein YB-1. J Mol Biol 2002;316:317-26.
16. Yarden Y. Biology of Her-2 and its importance in breast cancer. Oncology 2001;61:1-13.
17. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like bustype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74.
18. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science 1987; 235:177-82.
19. Kersting C, Tidow N, Schmidt H, et al. Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma. Lab Invest 2004;84:582-7.
20. Slamon DJ, Godalphin W, Jone LA, et al. Studies of the HER-2/new proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
21. Bosher JM, Williams T, Hurst HC. The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. Proc Natl Acad Sci U S A 1995;92:744-7.
22. Xing X, Want SC, Xia W, et al. The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat Med 2000;6:189-95.
23. Vernimmen D, Gueders M, Pisvin S, Delvenne P, Winkler R. Different mechanisms are implicated in ErbB2 gene overexpression in breast and in other cancers. Br J Cancer 2003;89:899-906.
24. Chen LL, Clawson ML, Bilgrami S, Carmichael GA. Sequence specific single stranded DNA-binding protein that is responsive to epidermal growth factor recognizes an S1 nuclease-sensitive region in the epidermal growth factor receptor promoter. Cell Growth Differ 1993;4:975-83.
25. Zenz RH, Scheuch P, Martin C, et al. c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell 2003;4:879-89.
26. Kageyama R, Merlino GT, Pastan I. Epidermal growth factor (EGF) receptor gene transcription: requirement for Sp1 and EGF receptor specific factor. J Biol Chem 1988;263:6329-36.
27. Berquin IM, Pang B, Dzuibinski ML, et al. Y-box binding protein 1 confers EGF independence to human mammary epithelial cells. Oncogene 2005;24:3177-86.
28. Makretsov N, Gilks CB, Coldman AJ, Hayes M, Hunt D. Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Hum Pathol 2003;34:1001-8.
29. Nielsen TO, Cheang MCU Hsu FD, et al. Epidermal growth factor receptor and basal breast cancer: prognosis on a large population based series. Clin Cancer Res 2004;10:5361-74.
30. Kucab JE, Lee C, Chen CS, et al. Celecoxib analogues disrupt Akt signaling which is commonly activated in primary breast tumors. Breast Cancer Res 2005;7 no 5:R796-807.
31. Oh JS, Buchel P, Martin K, et al. Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells. Neoplasia 2002;4, no. 3:204-17.
32. Chrysogelos SA. Chromatin structure of the EGFR gene suggests a role for intron 1 sequences in its regulation in breast cancer cells. Nucleic Acids Res 1993;21, no 24:5739-41.
33. Yakes FM. Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1 and antitumor action. Cancer Res 2002;62:4132-41.
34. Huber E, Vlasny D, Jeckel S, Stubenrauch F, Iftner T. Gene profiling of cottontail rabbit papillomavirus-induced carcinomas identifies upregulated genes directly involved in stromal invasion as shown by small interfering RNA-mediated gene silencing. J Virol 2004;78 no 14:7478-89.
35. Janz M, Harbeck N, Dettmar PB, et al. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 2002;97:278-82.
36. Van't Veer LJ, Dia H, Van de Vijver JM, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
37. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.
38. Bertucci F, Finetti P, Rougemount J, et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 2005;65:2170-8.
39. Rao GS, Murray S, Ethier SP. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys 2000;48 no. 5:1519-28.
40. Hurst HC. Update on Her-2 as a target for cancer therapy: the ERB-B2 promoter and its exploitation for cancer treatment. Breast Cancer Res 2001;3:395-8.
41. Pasleau F, Groteclaes M, Gol-Winkler R. Expression of the c-cerbB2 gene in the BT474 human mammary tumor cell line: measurement of c-cerbB2 mRNA half-life. Oncogene 1993:8 no 4:849-54.
42. Shepherd TG, Kockeritz L, Szrajber MR, Muller WJ, Hassell JA. The pea3 subfamily ets genes are required for Her-2/Neu mediated mammary oncogenesis. Curr Biol 2001;11:1739-48.
43. Fauquette V, Perrais M, Cerulis S, et al. The antagonistic regulation of human MUC4 and ErbB-2 genes by the Ets protein PEA3 in pancreatic cancer cells: implications for the proliferation/differentiation balance in the cells. Biochem J 2005;386:35-45.
44. Mertens PR, Alfonso-Jaum MA, Steinmann K, Lovett DH. A synergistic interaction of transcription factors AP2 and YB-1 regulates gelatinase A enhancer-dependent transcription. J Biol Chem 1998;273:32957-65.